acancy on the Audit Committee. The Company fully expects to regain compliance with Nasdaq Rule 5605(c)(2)(A) within the cure period provided for in Nasdaq Rule 5605(c)(4)(B). Item 3.02 Unregistered Sales of Equity Securities. The information in Item 1.01 regarding the New Notes Shares and Warrants is inc